In addition, Pat thinks then beginner investors should cultivate two important qualities: a healthy sense of skepticism and patience.
[text_ad]
Investors should approach all investments with a healthy sense of skepticism. This can help keep you out of fraudulent stocks that masquerade as high-quality stocks. It will also keep you out of legally operated, but poorly managed, companies that promise more than they can possibly deliver.
If you are a new investor, you should also realize that losing patience can cause you to sell your best choices right before a big rise. All too often, investors buy a promising stock just as it enters a period of price stagnation. Even the best-performing stocks run into these unpredictable phases from time to time. They move mainly sideways in a wide range for months or years before their next big rise begins. (Stock brokers often refer to these stocks as “dead money.”)
If you lack patience, you run a big risk of selling your best choices in the midst of one of these phases, prior to the next big move upward. If you lose patience and sell, you are particularly likely to do so in the low end of the trading range, when stock prices have weakened and confidence in the stock has waned.
[text_ad]
Established in 1930, it is one of the oldest closed-end investment companies in North America....
In July 2011 we analyzed Pfizer’s prospects and felt it offered our readers a strong combination of long-term growth and income. We—and you—have not been disappointed. The stock touched a new all-time high of $51.86 in August 2021, which is an impressive 159.3% above the $20 that the stock was trading for when we first recommended it in our Wall Street Stock Forecaster newsletter....
Sleep apnea gets far less media attention than other health issues such as high blood pressure, obesity, diabetes, depression, stroke and heart problems. But now, more and more public and private health insurers have begun to recognize, publicize and pay for sleep apnea treatment....
Canadian National Railway’s $33.6 billion U.S. takeover attempt for rival Kansas City Southern failed after regulators blocked a key condition of the deal. As a result, KCS has now agreed to merge with Canadian Pacific Railway—CN’s main competitor.
Investors tend to dislike the risk that comes with big acquisitions, and CN stock rallied on the news....
Its sales break down as follows: pharmaceuticals, 71%; vaccines, 17%; and consumer healthcare, 12%....